JAIME CANNON: Open Payments
NPI 1073894168 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,237 in 106 payments from 21 companies in 2025. Trend: 2023 $2,630 · 2024 $2,367 · 2025 $2,237
Food & beverage: $2,237
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 20 | $420 |
| GlaxoSmithKline, LLC. | 15 | $264 |
| Amgen Inc. | 15 | $225 |
| GENZYME CORPORATION | 7 | $160 |
| Regeneron Healthcare Solutions, Inc. | 7 | $141 |
| United Therapeutics Corporation | 6 | $140 |
| Grifols USA, LLC | 4 | $112 |
| Viatris Specialty LLC | 5 | $110 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $109 |
| Pulmonx Corporation | 1 | $108 |
Products named: TEZSPIRE, DUPIXENT, FASENRA, NUCALA, Tyvaso, Prolastin-C Liquid, TRELEGY ELLIPTA, YUPELRI.
Industry payments across AL — which companies pay providers there.
